Literature DB >> 10577593

Reconsidering the pathogenesis of ocular toxoplasmosis.

G N Holland1.   

Abstract

PURPOSE: To review recent observations regarding the sources of Toxoplasma gondii infection and rates of ocular involvement in cases of infection acquired after birth, and to reconcile them with older observations and widely held beliefs about the pathogenesis of ocular toxoplasmosis.
METHOD: A review of pertinent reports from the medical literature.
RESULTS: There are several potential sources and routes of infection, including inhalation of spores and ingestion of contaminated drinking water, that were previously unrecognized. Ocular involvement in cases of acquired infection appears to be more common than heretofore believed. A variety of host and parasitic factors may influence rates of ocular infection and the characteristics of ocular disease.
CONCLUSIONS: The scars from which recurrent toxoplasmic retinochoroiditis arise may be the result of remote, acquired infections in many cases, rather than the residua of congenital infections, as commonly assumed. A better understanding of the epidemiology of T. gondii infection, as well as the host and parasitic factors that influence disease presentation, is important for developing strategies for prevention and management of ocular toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577593     DOI: 10.1016/s0002-9394(99)00263-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  27 in total

1.  Rapid identification of virulent type I strains of the protozoan pathogen Toxoplasma gondii by PCR-restriction fragment length polymorphism analysis at the B1 gene.

Authors:  M E Grigg; J C Boothroyd
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

2.  Is ocular toxoplasmosis caused by prenatal or postnatal infection?

Authors:  R E Gilbert; M R Stanford
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  Acquired ocular toxoplasmosis in pregnancy.

Authors:  M Ramchandani; J B Weaver; D H M Joynson; P I Murray
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

4.  CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular toxoplasmosis.

Authors:  Kazumi Norose; Akitoshi Kikumura; Andrew D Luster; Christopher A Hunter; Tajie H Harris
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

Review 5.  Toxoplasmosis: A history of clinical observations.

Authors:  Louis M Weiss; Jitender P Dubey
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

6.  A 26-year-old man with a blind spot in his left eye.

Authors:  Alfred White; Timothy Saunders; Peter Pavan
Journal:  Digit J Ophthalmol       Date:  2013-09-25

7.  An ophthalmologist survey-based study of the atypical presentations and current treatment practices of ocular toxoplasmosis in India.

Authors:  Soumyava Basu; Jyotirmay Biswas; Uwe Pleyer; Avinash Pathangay; B Manohar Babu
Journal:  J Parasit Dis       Date:  2011-05-07

8.  In Vivo CRISPR Screen Identifies TgWIP as a Toxoplasma Modulator of Dendritic Cell Migration.

Authors:  Lamba Omar Sangaré; Einar B Ólafsson; Yifan Wang; Ninghan Yang; Lindsay Julien; Ana Camejo; Patricia Pesavento; Saima M Sidik; Sebastian Lourido; Antonio Barragan; Jeroen P J Saeij
Journal:  Cell Host Microbe       Date:  2019-10-09       Impact factor: 21.023

9.  Role of cytokines and major histocompatibility complex restriction in mouse resistance to infection with a natural recombinant strain (type I-III) of Toxoplasma gondii.

Authors:  Blima Fux; Cibele V Rodrigues; Ricardo W Portela; Neide M Silva; Chunlei Su; David Sibley; Ricardo W A Vitor; Ricardo T Gazzinelli
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  TgICMAP1 is a novel microtubule binding protein in Toxoplasma gondii.

Authors:  Aoife T Heaslip; Stephanie C Ems-McClung; Ke Hu
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.